Skip to main content
Erschienen in: Digestive Diseases and Sciences 1/2020

25.07.2019 | Original Article

Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C

verfasst von: Charlotte E. Costentin, Philippe Sogni, Bruno Falissard, Jean-Claude Barbare, Noelle Bendersky, Olivier Farges, Nathalie Goutte

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Data on alcohol-related HCC are limited.

Aims

Our aim was to describe the incidence, management, and prognosis of alcohol compared to Hepatitis C (HCV)-related HCC at a national level.

Methods

Incident cases of HCC were identified in French healthcare databases between 2009 and 2012 and analyzed retrospectively. Demographic data, type, location, and annual HCC-caseload of the hospitals where patients were first managed were retrieved. Survival of incident cases was computed from the time of diagnosis and adjusted for potential confounding variables.

Results

The study population included 14,060 incident cases of alcohol and 2581 HCV-related HCC. Alcohol-related HCC was more frequent than HCV-related HCC (29.37 and 5.39/100,000 adults/year, respectively) with an heterogeneous distribution on the French territory. The optimal treatment was less frequently curative (20.5% vs 35.9%; p < 0.001), and survival was significantly shorter (9.5 [9.0–10.0] versus 16.8 [15.5–18.7] months p < 0.001) in alcohol compared to HCV-related HCC, with marked variations between regions for a given risk factor. In multivariable analysis in the whole study population, curative treatment was a strong predictor of survival (adjusted HR 0.28 [0.27–0.30] months p < 0.001). Being managed at least once in a teaching hospital during follow-up was independently associated with receiving a curative treatment and survival.

Conclusion

In France, incidence of alcohol-related HCC is high and prognosis is poor compared to HCV-related HCC, with marked variations between regions. These results should guide future health policy initiatives pertaining to HCC care. Importantly, increasing patient’ referral in expert centers could increase chances to receive curative treatment and improve outcomes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol. 2017;3:1683–1691.PubMedPubMedCentral Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol. 2017;3:1683–1691.PubMedPubMedCentral
3.
Zurück zum Zitat EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef
4.
Zurück zum Zitat Rosa I, Denis J, Lesgourgues B, et al. A french multicentric longitudinal descriptive study of hepatocellular carcinoma management. The CHANGH cohort: preliminary results. Hepatology 2010:1144A (Abstract). Rosa I, Denis J, Lesgourgues B, et al. A french multicentric longitudinal descriptive study of hepatocellular carcinoma management. The CHANGH cohort: preliminary results. Hepatology 2010:1144A (Abstract).
6.
Zurück zum Zitat Goutté N, Sogni P, Bendersky N, Barbare JC, Falissard B, Farges O. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country. J Hepatol. 2017;66:537–544.CrossRefPubMed Goutté N, Sogni P, Bendersky N, Barbare JC, Falissard B, Farges O. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country. J Hepatol. 2017;66:537–544.CrossRefPubMed
7.
Zurück zum Zitat Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69:718–735.CrossRefPubMed Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69:718–735.CrossRefPubMed
9.
Zurück zum Zitat Bucci L, Garuti F, Camelli V, et al. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment Pharmacol Ther. 2016;43:385–399.CrossRefPubMed Bucci L, Garuti F, Camelli V, et al. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment Pharmacol Ther. 2016;43:385–399.CrossRefPubMed
10.
Zurück zum Zitat Ioannou GN, Green P, Lowy E, Mun EJ, Berry K. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS ONE. 2018;13:e0204412.CrossRefPubMedPubMedCentral Ioannou GN, Green P, Lowy E, Mun EJ, Berry K. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS ONE. 2018;13:e0204412.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Marot A, Henrion J, Knebel JF, Moreno C, Deltenre P. Alcoholic liver disease confers a worse prognosis than HCV infection and nonalcoholic fatty liver disease among patients with cirrhosis: an observational study. PLoS ONE. 2017;12:e0186715.CrossRefPubMedPubMedCentral Marot A, Henrion J, Knebel JF, Moreno C, Deltenre P. Alcoholic liver disease confers a worse prognosis than HCV infection and nonalcoholic fatty liver disease among patients with cirrhosis: an observational study. PLoS ONE. 2017;12:e0186715.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Costentin C, Mourad A, Lahmek P, et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective nationwide study. Cancer. 2018;124:1964–1972.CrossRefPubMed Costentin C, Mourad A, Lahmek P, et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective nationwide study. Cancer. 2018;124:1964–1972.CrossRefPubMed
13.
Zurück zum Zitat Ganne-Carrié N, Chaffaut C, Bourcier V, CIRRAL Group, et al. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol. 2018;69:1274–1283.CrossRefPubMed Ganne-Carrié N, Chaffaut C, Bourcier V, CIRRAL Group, et al. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol. 2018;69:1274–1283.CrossRefPubMed
14.
Zurück zum Zitat Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204–209.CrossRefPubMed Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204–209.CrossRefPubMed
15.
Zurück zum Zitat Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422.PubMed Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422.PubMed
16.
Zurück zum Zitat Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43:1303–1310.CrossRefPubMed Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43:1303–1310.CrossRefPubMed
17.
Zurück zum Zitat Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291–297.CrossRefPubMed Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291–297.CrossRefPubMed
18.
Zurück zum Zitat Sato T, Tateishi R, Yoshida H, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int. 2009;3:544–550.CrossRefPubMedPubMedCentral Sato T, Tateishi R, Yoshida H, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int. 2009;3:544–550.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21:793–799.CrossRefPubMedPubMedCentral Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21:793–799.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Yu EW, Chie WC, Chen TH. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients? Cancer J. 2004;10:317–325.CrossRefPubMed Yu EW, Chie WC, Chen TH. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients? Cancer J. 2004;10:317–325.CrossRefPubMed
21.
Zurück zum Zitat Trevisani F, De Notariis S, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002;97:734–744.CrossRefPubMed Trevisani F, De Notariis S, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002;97:734–744.CrossRefPubMed
22.
Zurück zum Zitat Tanaka H, Nouso K, Kobashi H, et al. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int. 2006;26:543–551.CrossRefPubMed Tanaka H, Nouso K, Kobashi H, et al. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int. 2006;26:543–551.CrossRefPubMed
23.
Zurück zum Zitat Wong GL, Wong VW, Tan GM, et al. Surveillance program for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int. 2008;28:79–87.CrossRefPubMed Wong GL, Wong VW, Tan GM, et al. Surveillance program for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int. 2008;28:79–87.CrossRefPubMed
25.
Zurück zum Zitat El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila JA. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011;60:992–997.CrossRefPubMed El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila JA. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011;60:992–997.CrossRefPubMed
26.
Zurück zum Zitat Wu CY, Hsu YC, Ho HJ, Chen YJ, Lee TY, Lin JT. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut. 2016;65:693–701.CrossRefPubMed Wu CY, Hsu YC, Ho HJ, Chen YJ, Lee TY, Lin JT. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut. 2016;65:693–701.CrossRefPubMed
27.
Zurück zum Zitat Mittal S, Kanwal F, Ying J, et al. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: a United States cohort. J Hepatol. 2016;65:1148–1154.CrossRefPubMedPubMedCentral Mittal S, Kanwal F, Ying J, et al. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: a United States cohort. J Hepatol. 2016;65:1148–1154.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Johnson P, Berhane S, Kagebayashi C, et al. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br J Cancer. 2017;116:441–447.CrossRefPubMedPubMedCentral Johnson P, Berhane S, Kagebayashi C, et al. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br J Cancer. 2017;116:441–447.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Costentin C, Layese R, Bourcier V, et al. Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study. Gastroenterology. 2018;155:e10.CrossRef Costentin C, Layese R, Bourcier V, et al. Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study. Gastroenterology. 2018;155:e10.CrossRef
30.
Zurück zum Zitat Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stal P. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int. 2014;35:1862–1871.CrossRef Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stal P. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int. 2014;35:1862–1871.CrossRef
31.
Zurück zum Zitat Eskesen AN, Bjøro K, Aandahl EM, Line PD, Melum E. Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway—a population-based cohort study. Cancer Epidemiol. 2014;38:741–747.CrossRefPubMed Eskesen AN, Bjøro K, Aandahl EM, Line PD, Melum E. Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway—a population-based cohort study. Cancer Epidemiol. 2014;38:741–747.CrossRefPubMed
32.
Zurück zum Zitat Singal AG, Yopp AC, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila).. 2012;5:1124–1130.CrossRefPubMedPubMedCentral Singal AG, Yopp AC, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila).. 2012;5:1124–1130.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65:875–884.CrossRefPubMed Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65:875–884.CrossRefPubMed
35.
Zurück zum Zitat Barbare JC, Franco D, André T, et al. Should cases of hepatocellular carcinoma be discussed by non specialize multidisciplinary team meetings? Bull Cancer. 2014;101:558–563.CrossRefPubMed Barbare JC, Franco D, André T, et al. Should cases of hepatocellular carcinoma be discussed by non specialize multidisciplinary team meetings? Bull Cancer. 2014;101:558–563.CrossRefPubMed
36.
Zurück zum Zitat Yopp AC, Mansour JC, Beg MS, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2013;21:1287–1295.CrossRefPubMedPubMedCentral Yopp AC, Mansour JC, Beg MS, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2013;21:1287–1295.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Davila JA, Kramer JR, Duan Z, et al. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57:1858–1868.CrossRefPubMed Davila JA, Kramer JR, Duan Z, et al. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57:1858–1868.CrossRefPubMed
39.
Zurück zum Zitat Piscaglia F, Svegliati-Baroni G, Barchetti A, HCC-NAFLD Italian Study Group, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63:827–838.CrossRefPubMed Piscaglia F, Svegliati-Baroni G, Barchetti A, HCC-NAFLD Italian Study Group, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63:827–838.CrossRefPubMed
40.
Zurück zum Zitat Weinmann A, Alt Y, Koch S, et al. Treatment and survival of nonalcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer. 2015;1:210.CrossRef Weinmann A, Alt Y, Koch S, et al. Treatment and survival of nonalcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer. 2015;1:210.CrossRef
41.
Zurück zum Zitat Barrault C, Lison H, Roudot-Thoraval F, et al. One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience. Eur J Gastroenterol Hepatol. 2017;29:1155–1160.CrossRefPubMed Barrault C, Lison H, Roudot-Thoraval F, et al. One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience. Eur J Gastroenterol Hepatol. 2017;29:1155–1160.CrossRefPubMed
42.
Zurück zum Zitat Beck F, Guignard R, Léon C, Richard J.-B. Atlas des usages de substances psychoactives 2010. Analyses régionales du Baromètre santé de l’Inpes. Saint-Denis: Inpes, coll. Études santé territoires, 2013 Beck F, Guignard R, Léon C, Richard J.-B. Atlas des usages de substances psychoactives 2010. Analyses régionales du Baromètre santé de l’Inpes. Saint-Denis: Inpes, coll. Études santé territoires, 2013
44.
Zurück zum Zitat Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373:2223–2233.CrossRefPubMed Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373:2223–2233.CrossRefPubMed
45.
Zurück zum Zitat Katikireddi SV, Whitley E, Lewsey J, Gray L, Leyland AH. Socioeconomic status as an effect modifier of alcohol consumption and harm: analysis of linked cohort data. Lancet Public Health.. 2017;2:e267–e276.CrossRefPubMedPubMedCentral Katikireddi SV, Whitley E, Lewsey J, Gray L, Leyland AH. Socioeconomic status as an effect modifier of alcohol consumption and harm: analysis of linked cohort data. Lancet Public Health.. 2017;2:e267–e276.CrossRefPubMedPubMedCentral
Metadaten
Titel
Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C
verfasst von
Charlotte E. Costentin
Philippe Sogni
Bruno Falissard
Jean-Claude Barbare
Noelle Bendersky
Olivier Farges
Nathalie Goutte
Publikationsdatum
25.07.2019
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2020
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05724-1

Weitere Artikel der Ausgabe 1/2020

Digestive Diseases and Sciences 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.